JPMorgan Sees 127% Upside in Camp4 Therapeutics as It Upgrades to Overweight on CMP-002 Potential
JPMorgan upgrades Camp4 to Overweight, sees strong upside from CMP-002, with trials planned in 2026 and promising early results.
/ 2 items
JPMorgan upgrades Camp4 to Overweight, sees strong upside from CMP-002, with trials planned in 2026 and promising early results.
Its new gene-boosting drug shows promise for rare brain disorders with no treatments yet.